{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T04:30:01Z","timestamp":1775622601563,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Ulm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ductal pancreatic adenocarcinoma (PDAC) still has a dismal prognosis even when deemed resectable. A cancer free resection margin (R0) is associated with a more favourable prognosis than the presence of tumour cells at resection margin (R1). However, the precise definition of the R0 status is still a matter of debate in PDAC. For a more accurate determination of R0 in PDAC the concept of circumferential resection margins (CRM) has been established and has been incorporated into the German national S3 guideline on exocrine pancreatic cancer. However, an international standardized nomenclature of CRM is still missing, and the clinical value of the CRM concept is not yet fully established. Here we evaluate whether the CRM status as defined in the national German S3 guideline corresponds with overall and progression free survival in PDAC using data from the regional cancer registry of the State of Baden W\u00fcrttemberg in Germany.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from the cancer registry of the State of Baden-W\u00fcrttemberg, Germany, were used to assess the relationship between CRM-status and progression free survival (PFS) as well as 3-year overall survival (OS) using documented patients diagnosed with resectable ductal adenocarcinoma of the pancreas between 2015 and 2020. Patients were residents of the State of Baden-W\u00fcrttemberg and underwent surgery for PDAC. The R-status was assessed according to the national German S3 guideline with R0 wide\/CRM- when CRM is &gt;\u20091\u00a0mm from the tumour, R0 narrow\/CRM\u2009+\u2009when CRM is \u2264 1\u00a0mm from the tumour and R1 when tumour cells are found at the resection margin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total we identified 1098 cases surgically treated for pancreatic cancer and fulfilling the inclusion criteria. 340 patients had an R0 wide\/CRM- resection, 410 patients an R0 narrow\/CRM\u2009+\u2009resection, and 348 patients an R1 resection. The R0 wide\/CRM- status was associated with a significantly increased median OS rate compared to the other two groups (51,5%, 37,4% and 26,7% for R0 wide\/CRM-, R0 narrow\/CRM\u2009+\u2009and R1, respectively). mPFS was also longer in the R0 wide\/CRM- group. These findings were robust with regards to grading and tumour location.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CRM is prognostic for patients with resectable PDAC making the pathological assessment of the R-status according to the CRM concept worthwhile.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12995-z","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T12:21:22Z","timestamp":1729167682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic value of the CRM-status in pancreatic ductal adenocarcinoma - data from a regional cancer registry"],"prefix":"10.1186","volume":"24","author":[{"given":"Jasmin","family":"Schuhbaur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Surovtsova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Seufferlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria","family":"Kokh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertrud","family":"Szotyori-Artz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Winzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliane","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldemar","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Tannapfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Morakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"12995_CR1","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK. AWMF). S3-Leitlinie zum exokrinen Pankreaskarzinom 2021 [Langversion 2.0:[Registrierungsnummer: 032-10OL]."},{"key":"12995_CR2","unstructured":"Robert Koch Institut ZfKZ. Krebs in Deutschland f\u00fcr 2017\/2018 2021 [13. Ausgabe:]"},{"issue":"11","key":"12995_CR3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00595-007-3745-8","volume":"38","author":"R Doi","year":"2008","unstructured":"Doi R, Imamura M, Hosotani R, Imaizumi T, Hatori T, Takasaki K, et al. Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial. Surg Today. 2008;38(11):1021\u20138.","journal-title":"Surg Today"},{"issue":"5","key":"12995_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/bjs.4484","volume":"91","author":"M Wagner","year":"2004","unstructured":"Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91(5):586\u201394.","journal-title":"Br J Surg"},{"issue":"8","key":"12995_CR5","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1002\/1097-0142(19950415)75:8<2069::AID-CNCR2820750807>3.0.CO;2-7","volume":"75","author":"JH Allema","year":"1995","unstructured":"Allema JH, Reinders ME, van Gulik TM, Koelemay MJ, Van Leeuwen DJ, de Wit LT, et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer. 1995;75(8):2069\u201376.","journal-title":"Cancer"},{"key":"12995_CR6","doi-asserted-by":"publisher","unstructured":"Kwon J, Lee SR, Park SY, Lee JH, Song KB, Hwang DW et al. Effect of resection margin status on recurrence pattern and survival in distal pancreatectomy for left-sided pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2023;30:633\u2013643. https:\/\/doi.org\/10.1002\/jhbp.1272. Epub 2022 Nov 30.","DOI":"10.1002\/jhbp.1272"},{"issue":"3","key":"12995_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/SLA.0000000000001731","volume":"265","author":"O Strobel","year":"2017","unstructured":"Strobel O, Hank T, Hinz U, Bergmann F, Schneider L, Springfeld C, et al. Pancreatic cancer surgery: the new R-status counts. Ann Surg. 2017;265(3):565\u201373.","journal-title":"Ann Surg"},{"issue":"3","key":"12995_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.pan.2020.01.004","volume":"20","author":"JK Pine","year":"2020","unstructured":"Pine JK, Haugk B, Robinson SM, Darne A, Wilson C, Sen G, et al. Prospective assessment of resection margin status following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma after standardisation of margin definitions. Pancreatology. 2020;20(3):537\u201344.","journal-title":"Pancreatology"},{"issue":"6","key":"12995_CR9","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1245\/s10434-008-9839-8","volume":"15","author":"I Esposito","year":"2008","unstructured":"Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15(6):1651\u201360.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"12995_CR10","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/bjs.5397","volume":"93","author":"CS Verbeke","year":"2006","unstructured":"Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232\u20137.","journal-title":"Br J Surg"},{"issue":"6","key":"12995_CR11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","volume":"155","author":"M Bockhorn","year":"2014","unstructured":"Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of pancreatic surgery (ISGPS). Surgery. 2014;155(6):977\u201388.","journal-title":"Surgery"},{"issue":"6","key":"12995_CR12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/00000658-199506000-00011","volume":"221","author":"CJ Yeo","year":"1995","unstructured":"Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995;221(6):721\u201331. discussion 31\u20133.","journal-title":"Ann Surg"},{"issue":"3","key":"12995_CR13","first-page":"263","volume":"52","author":"G Benassai","year":"2000","unstructured":"Benassai G, Mastrorilli M, Quarto G, Cappiello A, Giani U, Mosella G. Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Chir Ital. 2000;52(3):263\u201370.","journal-title":"Chir Ital"},{"issue":"4","key":"12995_CR14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1477-2574.2009.00055.x","volume":"11","author":"CS Verbeke","year":"2009","unstructured":"Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB (Oxford). 2009;11(4):282\u20139.","journal-title":"HPB (Oxford)"},{"issue":"8","key":"12995_CR15","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00423-019-01839-1","volume":"404","author":"M Schneider","year":"2019","unstructured":"Schneider M, Strobel O, Hackert T, Buchler MW. Pancreatic resection for cancer-the Heidelberg technique. Langenbecks Arch Surg. 2019;404(8):1017\u201322.","journal-title":"Langenbecks Arch Surg"},{"issue":"2","key":"12995_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00268-014-2808-4","volume":"39","author":"F Gebauer","year":"2015","unstructured":"Gebauer F, Tachezy M, Vashist YK, Marx AH, Yekebas E, Izbicki JR, et al. Resection margin clearance in pancreatic cancer after implementation of the Leeds Pathology Protocol (LEEPP): clinically relevant or just academic? World J Surg. 2015;39(2):493\u20139.","journal-title":"World J Surg"},{"key":"12995_CR17","doi-asserted-by":"crossref","unstructured":"Leonhardt CS, Niesen W, Kalkum E, Klotz R, Hank T, Buchler MW et al. Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis. BJS Open. 2022;6(2).","DOI":"10.1093\/bjsopen\/zrac010"},{"issue":"6","key":"12995_CR18","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1097\/SLA.0000000000002345","volume":"268","author":"IE Demir","year":"2018","unstructured":"Demir IE, Jager C, Schlitter AM, Konukiewitz B, Stecher L, Schorn S, et al. R0 versus R1 resection matters after pancreaticoduodenectomy, and less after distal or total pancreatectomy for pancreatic cancer. Ann Surg. 2018;268(6):1058\u201368.","journal-title":"Ann Surg"},{"issue":"1","key":"12995_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00423-024-03320-0","volume":"409","author":"SA Safi","year":"2024","unstructured":"Safi SA, Alexander A, Neuhuber W, Haeberle L, Rehders A, Luedde T, et al. Defining distal splenopancreatectomy by the mesopancreas. Langenbecks Arch Surg. 2024;409(1):127.","journal-title":"Langenbecks Arch Surg"},{"issue":"6","key":"12995_CR20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1055\/a-1771-6811","volume":"60","author":"T Seufferlein","year":"2022","unstructured":"Seufferlein T, Mayerle J, Bock S, Brunner T, Ettrich TJ, Grenacher L, et al. S3-Leitlinie zum exokrinen pankreaskarzinom \u2013 kurzversion 2.0 \u2013 dezember 2021, AWMF-Registernummer: 032\/010OL. Z Gastroenterol. 2022;60(6):991\u20131037.","journal-title":"Z Gastroenterol"},{"key":"12995_CR21","unstructured":"Wittekind C, Meyer HJ, editors. TNM Klassifikation maligner Tumoren 7. Auflage. 2010(Wiley-Blackwell)."},{"key":"12995_CR22","unstructured":"Wittekind CH. TNM Klassifikation maligner Tumoren 8. Auflage. 2017."},{"issue":"17","key":"12995_CR23","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1200\/JCO.2008.20.5104","volume":"27","author":"DK Chang","year":"2009","unstructured":"Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol. 2009;27(17):2855\u201362.","journal-title":"J Clin Oncol"},{"issue":"4","key":"12995_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.pan.2021.02.024","volume":"21","author":"SA Safi","year":"2021","unstructured":"Safi SA, Haeberle L, Fluegen G, Lehwald-Tywuschik N, Krieg A, Keitel V, et al. Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. Pancreatology. 2021;21(4):787\u201395.","journal-title":"Pancreatology"},{"issue":"1","key":"12995_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","volume":"34","author":"T Seufferlein","year":"2023","unstructured":"Seufferlein T, Uhl W, Kornmann M, Algul H, Friess H, Konig A, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2023;34(1):91\u2013100.","journal-title":"Ann Oncol"},{"issue":"11","key":"12995_CR26","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40(11):1220\u201330.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12995-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T12:21:29Z","timestamp":1729167689000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12995-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12995"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12995-z","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The State Cancer Registry has the task of continuously processing data concerning the treatment and clinical course of cancer as well as evaluating and making these data available for the purpose of cancer treatment [(State Cancer Registry Act of Baden W\u00fcrttemberg, Section 1 []]. In addition, the Clinical State Cancer Registry can provide anonymized and aggregated data and evaluations for the purpose of health services research (State Cancer Registry Act of Baden W\u00fcrttemberg, Section 6 []). There was never any access to raw data for external parties. The data is processed exclusively in the Clinical Register Office and discussed in anonymized and aggregated form. Ethical review and approval were waived for this study, due to the deidentified information of the patients included in the BW-database.This study adheres to the relevant guidelines according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1280"}}